BIRC5 and cancer: Although BIRC5 is an intracellular protein and therefore not a good target for CAR-T therapies, BIRC5-peptide mediated immunotherapy has been shown to exhibit low toxicity in clinical trial and can increase BIRC5 peptide-specific CTLs that kill cancer cells [59].